DTU Logo
Publications | Academic Presentations | Slidesets | Webcasts

Publications (332 of 332)


Search Publications :
ACE
On the potential of acarbose to reduce cardiovascular disease
Eberhard Standl, Michael J Theodorakis, Michael Erbach, Oliver Schnell and Jaakko Tuomilehto
Cardiovascular Diabetology 2014; (online)
[Full text]
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
Prof John J V McMurray MD, Prof Hertzel C Gerstein MD, Prof Rury R Holman FRCP, Prof Marc A Pfeffer MD
The Lancet 2014; (online)
[Full text]
NAVIGATOR
Role of diuretics, β-blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
Lan Shen, Bimal R Shah, Eric M Reyes, Laine Thomas, Daniel Wojdyla, Peter Diem, Lawrence A Leiter, Bernard Charbonnel, Viacheslav Mareev, Edward S Horton, Steven M Haffner, Vladimir Soska, Rury Holman, M Angelyn Bethel, Frank Schaper, Jie-Lena Sun, John JV McMurray, Robert M Califf, Henry Krum
British Medical Journal 2013; (online)
[Full text]
2014Review
First-time heart failure increases risk of diabetes mellitus
Rury R. Holman
Nat. Rev. Endocrinol. 2014;10:453-454
ACE
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Rury R Holman, Mary A Bethel, Juliana CN Chan, Jean-Louis Chiasson, Zoë Doran, Junbo Ge, Hertzel Gerstein, Yong Huo, John J McMurray, Lars Ryden, Winitha Liyanage, Stefan Schröder, Michal Tendera, Michael J Theodorakis, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan for the ACE Study Group
American Heart Journal 2014;168:23-29
[Full text]
NAVIGATOR
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR.
Huffman KM, Sun JL, Thomas L, Bales CW, Califf RM, Yates T, Davies MJ, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Haffner SM, Kraus WE.
Metabolism 2014;63:554-561
[Full text]
Cardiovascular Outcome Trials of Glucose Lowering Agents or Strategies in Type 2 Diabetes
Rury R Holman, Harald Sourij, Robert M Califf
Lancet 2014;383:2008-17
NAVIGATOR
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis
Thomas Yates, Steven M Haff ner, Phillip J Schulte, Laine Thomas, Kim M Huff man, Connie W Bales, Robert M Califf , Rury R Holman, John J V McMurray, M Angelyn Bethel, Jaakko Tuomilehto, Melanie J Davies, William E Kraus
Lancet 2014;383:1059-66
[Full text]
CAMERA
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial
David Preiss, Suzanne M Lloyd, Ian Ford, John J McMurray, Rury R Holman, Paul Welsh, Miles Fisher, Chris J Packard, Naveed Sattar
Lancet Diabetes & Endocrinology 2014;2:116-124
[Full text]
UKPDS 83
Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83)
T. M. E. Davis, R. L. Coleman and R. R. Holman for the UKPDS Group
Diabetic Medicine 2014;31:200-207
[Full text]
2013TECOS
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman
American Heart Journal 2013;166:983-989.e7
[Full text]
NAVIGATOR
Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial
Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ
American Heart Journal 2013;166:935-940.e1
NAVIGATOR
Predictors of Stroke in Patients With Impaired Glucose Tolerance
David Preiss, Thomas D. Giles, Laine E. Thomas, Jie-Lena Sun, Steven M. Haffner, Rury R. Holman, Eberhard Standl, Theodore Mazzone, Guy E. Rutten, Gianni Tognoni, Fu-Tien Chiang, John J.V. McMurray, Robert M. Califf
Stroke 2013;44:2590-2593
UKPDS 82
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM
Diabetologia 2013;56:1925-1933
[Full text]
NAVIGATOR
A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk
Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Kahn SE, Levitt NS, McMurray JJ, Califf RM, Raptis SA, Thomas L, Sun JL, Haffner SM
Am J Cardiol 2013;112:231-237
[Full text]
Letter
Metformin and mortality
R. J. Stevens, B. J. Cairns , R. R. Holman
Diabetologia 2013;56:939-940
UKPDS
Temporal Validation of the UKPDS Outcomes Model Using 10-Year Post trial Monitoring Data
Leal J, Hayes AJ, Gray AM, Holman RR, Clarke PM.
Diabetes Care 2013;36:1541-1546
[Full text]
TRG
Evaluation of a Self-Administered Oral Glucose Tolerance Test
M. Angelyn Bethel, Hermione C. Price, Harald Sourij, Sarah White, Ruth L. Coleman, Arne Ring, Irene E. C. Kennedy, Lynne Tucker, and Rury R. Holman
Diabetes Care 2013;36:1483-1488
[Full text]
UKPDS 79
Prognostic Significance of Silent Myocardial Infarction in Newly-Diagnosed Type 2 Diabetes: UKPDS 79
Timothy M.E. Davis; Ruth L. Coleman; Rury R. Holman
Circulation 2013;127:980-987
[Full text]
Review
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive
Holman RR
Nature Reviews Endocrinology 2013;9:67-68
[Full text]
2012NAVIGATOR
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
David Preiss, Laine E Thomas, Jie-Lena Sun, Steven M Haffner, Rury R Holman, Eberhard Standl, Lawrence A Leiter, Theodore Mazzone, Guy E Rutten, Gianni Tognoni, Felipe A Martinez, Fu-Tien Chiang, Robert M Califf, John J McMurray
BMJ Open 2012;2:e001925
[Full text]
4-T
Disseminating results to clinical trial participants: a qualitative review of patient understanding in a post-trial population
Julie Lorraine Darbyshire, Hermione Clare Price
BMJ Open 2012;2:e001252
[Full text]
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
R.J. Stevens, R.Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, R.P. Camisasca, F.L. Crowe, A.J. Farmer, S. Harrison, J.A. Hirst, P. Home, S.E. Kahn, J.H. McLellan, R. Perera, A. Plüddemann, A. Ramachandran, N.W. Roberts, P.W. Rose, A. Schweizer, G. Viberti, R. R. Holman
Diabetologia 2012;55:2593-2603
[Full text]
NAVIGATOR / DREAM
Letter to the Editor - Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
John J.V. McMurray, Robert M. Califf, Angelyn M. Bethel, Steven M. Haffner, Rury R. Holman
The Journal of Clinical Hypertension 2012;14:731
[Full text]
NAVIGATOR
Correspondence: Prediabetes and the risk of diabetes.
John JV McMurray, Steven M Haffner, Robert M Califf, Rury R Holman
The Lancet 2012;380:1225-1226
[Full text]
Editorial: Warning signals from clinical trials: all that glitters is not gold (Chinese translation)
Rury R Holman
Chinese Journal of Diabetes Mellitus 2012;4:513-516
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.
van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CN, Guigas B, Slagboom PE, Durrington P, Calle RA, Neil A, Hitman G, Livingstone SJ, Colhoun H, Holman RR, McCarthy MI, Dekker JM, 't Hart LM, Pearson ER.
Diabetologia 2012;55:1971-7
[Full text]
Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice
Hermione C Price, Catherine Gorst, Usha Ayyagari, Jonathan Levy and Rury R Holman
Practical Diabetes 2012;29:61-64
[Full text]
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC; TIDE Trial Investigators.
Diabetologia 2012;55:36-45
[Full text]
Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice
M. Angelyn Bethel & Harald Sourij
Current Cardiology Reports 2012;14:59-69
[Full text]
Letter in response to Wannamethee et al: Women develop diabetes at higher BMIs than men
H. Sourij, R. R. Holman
Diabetologia 2012;55:855-6
[Full text]
4-T
Understanding the outcomes of multi-centre clinical trials: a qualitative study of health professional experiences and views.
Lawton J, Jenkins N, Darbyshire J, Farmer A, Holman R, Hallowell N
Social Science & Medicine 2012;74:574-81
[Full text]
2011All That Glitters Is Not Gold: Why we need better trials and reporting
Rury R Holman
Diabetes Voice 2011;56:32
[Full text]
4-T
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Farmer AJ, Oke J, Stevens R, Holman RR
Diabetes, Obesity and Metabolism 2011;13:1136-1141
[Full text]
ADOPT
Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
John M. Lachin, Giancarlo Viberti, Bernard Zinman, Steven M. Haffner, R. Paul Aftring, Gitanjali Paul, Barbara G. Kravitz, William H. Herman, Rury R. Holman, Steven E. Kahn, ADOPT
Clin J Am Soc Nephrol 2011;6:1032-40
[Full text]
ADOPT
Effects Of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR; and the ADOPT Study Group
Diabetes 2011;60:1552-1560
[Full text]
4-T
Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
Julia Lawton, Nicholas Jenkins, Julie L Darbyshire, Rury R Holman, Andrew J Farmer and Nina Hallowell
Trials 2011;12:
[Full text]
DREAM
Incidence of Diabetes Following Ramipril and Rosiglitazone Withdrawal
Rury R Holman FRCP, B Zinman, S Yusaf, P Sheridan, S Anand, J Bosch, I Conget, M Davies, V Pirags, J Pogue, P Zimmet, HC Gerstein.
Diabetes Care 2011;34:1265-1269
[Full text]
4-T
Patients' experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study
N. Jenkins, N. Hallowell, A. J. Farmer, R. R. Holman, J. Lawton
Diabetic Medicine 2011;28:543-548
[Full text]
Impact of personalised cardiovascular disease risk estimates on physical activity-a randomised controlled trial
Hermione C Price, Simon J Griffin, Rury R Holman
Diabetic Medicine 2011;28:363-372
[Full text]
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals
The ARB Trialists Collaboration
Journal of Hypertension 2011;29:623-635
2010UKPDS
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group & The Wellcome Trust Case Control Consortium
Nature Genetics 2010;43:117-120
[Full text]
AFORRD
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled trial
H.A.W. Neil, U. Ceglarek, J. Thiery, S. Paul, A. Farmer, R. R Holman
Atherosclerosis 2010;213:512-517
Letter
Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions? Reply to Wägner AM, Mauricio D
A. J. Farmer & D. S. Lasserson & R. R. Holman
Diabetologia 2010;53:1004-5
[Full text]
NAVIGATOR
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010;362:1463-76
[Full text] [Presentation] [Slides]
NAVIGATOR
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
The NAVIGATOR Study Group
N Engl J Med 2010;362:1477-90
[Full text] [Presentation] [Slides]
4-T
Initiating insulin as part of the Treating to Target in Type 2 Diabetes (4-T) trial: A interview study of patients' and health care professionals' experiences
Nicholas Jenkins, Nina Hallowell, Andrew J. Farmer, Rury R. Holman, Julia Lawton
Diabetes Care 2010;33:2178-2180
[Full text]
Recommendations for Biomarker Identification and Qualification in Clinical Proteomics
Harald Mischak, Günter Allmaier, Rolf Apweiler, Teresa Attwood, Marc Baumann, Ariela Benigni, Samuel E. Bennett, Rainer Bischoff, Erik Bongcam-Rudloff, Giovambattista Capasso, Joshua J. Coon, Patrick D'Haese, Anna F. Dominiczak, Mohammed Dakna, Hassan Dihazi, Jochen H. Ehrich, Patricia Fernandez-Llama, Danilo Fliser, Jorgen Frokiaer, Jerome Garin, Mark Girolami, William S. Hancock, Marion Haubitz, Denis Hochstrasser, Rury R. Holman, John P. A. Loannidis, Joachim Jankowski, Bruce A. Julian, Jon B. Klein, Walter Kolch, Theo Luider, Ziad Massy, William B. Mattes, Franck Molina, Bernard Monsarrat, Jan Novak, Karlheinz Peter, Peter Rossing, Marta Sánchez-Carbayo, Joost P. Schanstra, O. John Semmes, Goce Spasovski, Dan Theodorescu, Visith Thongboonkerd, Raymond Vanholder, Timothy D. Veenstra, Eva Weissinger, Tadashi Yamamoto, Antonia Vlahou
Science Translational Medicine 2010;2:46ps42
Risk communication: Why, what and how?
Hermione C Price
Diabetes & Primary Care 2010;12:100-104
[Full text]
Life Expectancy in Individuals with Type 2 Diabetes: Implications for Annuities
Hermione C. Price, Philip M. Clarke, Alastair M. Gray and Rury R. Holman
Medical Decision Making 2010;30:409-14
[Full text]
NAVIGATOR
Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials
Henry Krum, John J.V. McMurray, Edward Horton, Teresa Gerlock, Bjoern Holzhauer, Lineke Zuurman, Steven M. Haffner, M. Angelyn Bethel, Rury R. Holman, Robert M. Califf
Cardiovascular Therapeutics 2010;28(2):124-132
[Full text]
Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis
Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ
Lancet 2010;375:1365-1374
Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes
Aparna Pal, Christina Dudley, Mary Selwood, Beryl Barrow, Rhiannon Klyne, Jilly Grew, Andrew Farmer, Mark McCarthy, Anna Gloyn, Katharine Owen
Diabetes Care 2010;33:252-257
[Full text]
ADOPT
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial).
Steven E. Kahn, Steven M. Haffner, Giancarlo Viberti, William H. Herman, John M. Lachin, Barbara G. Kravitz, Dahong Yu, Gitanjali Paul, Rury R. Holman, Bernard Zinman and for the ADOPT Study Group
Diabetes Care 2010;33:177-183
[Full text] [Abstract]
2009Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman
Clinical Diabetes 2009;27:4-16
[Full text]
Exenatide Case Report
Price HC, Holman RR
International Diabetes 2009;15:15
[Full text]
ADOPT
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman, Steven M. Haffner, William H. Herman, Rury R. Holman, John M. Lachin, Barbara G. Kravitz, Gitanjali Paul, Nigel P. Jones, R. Paul Aftring, Giancarlo Viberti, Steven E. Kahn, and the A Diabetes Outcome Progression Trial Study Group
J Clin Endocrinol Metab 2009;95:134-142
[Full text]
Perceptions of heart attack risk amongst individuals with diabetes
Hermione C Price, Christina Dudley, Beryl Barrow, Simon J Griffin & Rury R Holman
Primary Care Diabetes 2009;3:239 -244
[Full text]
NAVIGATOR
Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population
M. A. Bethel, P. Deedwania, N. S. Levitt, O. Schmitz, A. Huntsman-Labed, R. M. Califf, S. M. Haffner and P. Diem for the NAVIGATOR Study Groupp
Diabetic Medicine 2009;26:1204-1211
[Full text] [Abstract]
4-T
Presenting the results of clinical trials to participants
Julie L Darbyshire, Rury R Holman and Hermione C Price
Clin Med 2009;9:415-416
[Full text]
Meta-analysis
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull, C. Abraira, R. J. Anderson, R. P. Byington, J. P. Chalmers, W. C. Duckworth, G. W. Evans, H. C. Gerstein, R. R. Holman, T. E. Moritz, B. C. Neal, T. Ninomiya, A. A. Patel, S. K. Paul, F. Travert and M. Woodward
Diabetologia 2009;52:2288-2298
[Full text]
4-T
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman, Andrew J. Farmer, Melanie J. Davies, Jonathan C. Levy, Julie L. Darbyshire, Joanne F. Keenan, and Sanjoy K. Paul for the 4-T Study Group
N Eng J Med 2009;361:1736-47
[Full text] [Slides]
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses
Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ
Diabetologia 2009;52:1990-2000
[Full text]
Cardiovascular disease risk estimation: Why, when and how?
Price HC
Diabetes and Primary Care 2009;11:218-223
[Full text]
Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes
Price HC, Dudley C, Barrow B, Kennedy IA, Griffin SJ, Holman RR
Family Practice 2009;26:351-358
[Full text] [Abstract]
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, DeFronzo R, Genuth S, Holman R, Linong Ji, Kirkman S, Knowler WC, Schatz D, Shaw J, Sobngwi E, Steffes M, Vaccaro O, Wareham N, Zinman B, Kahn R
Diabetes Care 2009;32:1327-1334
[Full text]
Community Cardiology Clinics for Secondary Prevention of Coronary Heart Disease and Heart Failure in Primary Care
Khunti K, MD, Stone M, Paul S, Squire I.
Cardiology Review 2009;25:64-67
[Full text]
UKPDS Letter
Addition of Insulin to Oral Therapy in Type 2 Diabetes
Holman RR, Matthews DM, Neil HAW
N Eng J Med 2009;360:418
HTA Report
Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial
Farmer AJ, Wade AN, French DP, Simon J, Yudkin P, Gray A, Craven A, Goyder L, Holman RR, Mant D, Kinmonth A-L and Neil HAW, on behalf of the DiGEM Trial Group
Health Technology Assessment 2009;13:1-71
[Full text]
Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.
Paul S, Coleman RL, Price HC, Farmer AJ
Diabetes Care 2009;32:e60
[Full text] [Abstract]
European physicians overestimate life expectancy and the likely impact of interventions in individuals with Type 2 diabetes
Price HC, Thorne KI , Dukat A, Kellett J
Diabetic Medicine 2009;26:453-455
[Full text]
Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw K, Wareham NJ, Griffin SJ
Diabetes Care 2009;32:708-713
[Full text] [Abstract]
Editorial
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?
Price HC, Holman RR
Nature Clinical Practice Cardiovasc Medicine 2009;6:168-169
[Full text] [Abstract]
Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes.
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009;52:394-397
[Full text] [Abstract]
Review
Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes
Hartweg J, Farmer AJ, Holman RR, Neil A
Curr Opin Lipidol 2009;20:30-38
Algorithm
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetologia 2009;52:17-30
[Full text]
Algorithm
Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B
Diabetes Care 2009;32:193-203
[Full text] [Abstract]
EDIT
Prevalence of Glucokinase (GCK) Mutations in Individuals Screened for Fasting Hyperglycaemia
Gloyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker L, Ellard S, Holman RR
Diabetologia 2009;52:172-174
[Full text]
AFORRD
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA on behalf of the AFORRD study group
Diabetologia 2009;52:50 - 59
[Full text] [Abstract]
2008The cost-effectiveness a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care
D A Turner, S Paul, M A Stone, A Juarez-Garcia, I Squire, K Khunti
Heart 2008;94:1601-1606
[Full text] [Abstract]
Analysis of bedside entertainment services' effect on post cardiac surgery physical activity: a prospective, randomised clinical trial
Sotiris Papaspyros, Shitansu Uppal, Shakeeb A. Khan, Sanjoy Paul, David J. O'Regan
European Journal of Cardiothoracic Surgery 2008;34:1022-1026
[Full text] [Abstract]
4-T Letter
Addition of Insulin to Oral Therapy in Type 2 Diabetes
Holman RR
The New England Journal of Medicine 2008;358:1198
[Full text]
Impact of comorbid diabetes on quality of life and perception of angina pain in people with angina registered with general practitioners in the UK
Stone MA, Khunti K, Squire I, Paul S
Qual Life Res 2008;17:887-894
Predictability of price of tea from sensory assessments and biochemical information using data-mining techniques
Sanjoy K Paul
J Sci Food Agric 2008;88:1354-1362
[Full text]
UKPDS 81
Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, H. Andrew W. Neil and David R. Matthews
N Eng J Med 2008;359:1565-76
[Full text] [Slides]
UKPDS 80
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Rury R. Holman, Sanjoy K. Paul, M. Angelyn Bethel, David R. Matthews and H. Andrew W. Neil
N Eng J Med 2008;359:1577-89
[Full text] [Slides]
NAVIGATOR
Determining the most appropriate components for a composite clinical trial outcome
M. Bethel, R. Holman, S. Haffner, R. Califf, A. Huntsman-Labed, T. Hua, J. McMurray
Am Heart J 2008;156:633-40
[Full text]
NAVIGATOR
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John McMurray, Anil Duggal, Rury R. Holman, for the NAVIGATOR Study Group
Am Heart J 2008;156:623-32
[Full text]
The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD. A Pilot 2x2 Factorial
Hermione C Price, Lynne Tucker, Simon J Griffin and Rury R Holman
Cardiovascular Diabetology 2008;7:21
[Full text] [Abstract]
ADOPT
Rosiglitazone Associated Fractures in Type 2 Diabetes:an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Steven E. Kahn, Bernard Zinman, John M. Lachin, Steven M. Haffner, William H. Herman, Rury R. Holman, Barbara G. Kravitz, Dahong Yu, Mark A. Heise, R. Paul Aftring, Giancarlo Viberti, and for the A Diabetes Outcome Progression Trial (ADOPT) Study Group
Diabetes Care 2008;31:845-851
[Full text] [Abstract]
DREAM
Effects of Rampiril and Rosiglitazone on Cardiovascular and Renal outcomes in People with Impaired Glucose Tolerance and Impaired Fasting Glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
DREAM Trial Investigators; G.R. Dagenais, H.C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, M. Keltai, E. Lonn, S. McFarlane, M. McQueen, K. Teo, P. Sheridan, J. Bosch, J. Pogue, S. Yusuf
Diabetes Care 2008;31:1007-1014
[Full text] [Abstract]
Clinical Decisions. Management of Type 2 Diabetes
Ronald B. Goldberg, Rury Holman, Daniel J. Drucker
N Eng J Med 2008;358:293-7
[Full text]
Algorithm
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy : Update regarding the thiazolidinediones
D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin and B. Zinman
Diabetologia 2008;51:8-11
[Full text]
Algorithm
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy : Update regarding the thiazolidinediones
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin and Bernard Zinman
Diabetes Care 2008;31:173-175
[Full text]
2007Outcomes Model / Risk Engine
Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.
The Mount Hood 4 Modeling Group
Diabetes Care 2007;30:1638-1646
[Full text]
Factors predictive of voiding problems following insertion of tension-free vaginal tape
A. Shukla, S. Paul, A. Nishtar, J. Bibby
International Journal of Gynaecology & Obstetrics 2007;96:122-126
[Full text] [Abstract]
UKPDS
Metformin as First Choice in oral Diabetes Treatment: the UKPDS experience
Holman R
Journ Annu Diabetol Hotel Dieu 2007;13:13-20
[Full text]
Recommendations for designing tables that report randomized trials
E. S. Johnson, I. M. Stratton
Diabetic Medicine 2007;24:1309-1312
[Full text]
Cardiovascular Benefits of Metformin
Holman RR
in Metformin - The Gold Standard, Editors CJ Bailey, IW Campbell, JC Chan, JA Davidson, HCS Howlett, P Ritz 2007;15
UKPDS 78
Impact of the Metabolic Syndrome on Macrovascular and Microvascular Outcomes in Type 2 Diabetes Mellitus. UKPDS 78
Carole A. Cull, Christine C. Jensen, Ravi Retnakaran and Rury R. Holman
Circulation 2007;116:2119-2126
[Full text] [Abstract]
4-T
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Rury R. Holman, Kerensa I. Thorne, Andrew J. Farmer, Melanie J. Davies, Joanne F. Keenan, Sanjoy Paul, Jonathan C. Levy for the 4-T Study Group
N Eng J Med 2007;357:1716-30
[Full text] [Abstract] [Slides]
Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial
Kamlesh Khunti, Margaret Stone, Sanjoy Paul, Jan Baines, Louise Gisborne, Azhar Farooqi, Xiujie Luan and Iain Squire
Heart 2007;93:1398-1405
[Full text] [Abstract]
Stability of soluble adhesion molecules, selectins and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies
Janine Hartweg, Michael Gunter, Rafael Perera, Andrew Farmer, Carole Cull, Casper Schalkwijk, Astrid Kok, Harry Twaalfhoven, Rury Holman and Andrew Neil
Clinical Chemistry 2007;53:1858-60
[Full text]
DiGEM
Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial
Andrew Farmer, Alisha Wade, Elizabeth Goyder, Patricia Yudkin, David French, Anthea Craven, Rury Holman, Ann-Louise Kinmonth, Andrew Neil on behalf of the Diabetes Glycaemic Education and Monitoring Trial Group
British Medical Journal 2007;335:132-6
[Full text]
UKPDS 77
GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.
M. Desai, C. A. Cull, V. A. Horton, M. R. Christie, E. Bonifacio, V. Lampasona, P. J. Bingley, J. C. Levy, I. R. Mackay, P. Zimmet, R. R. Holman and A. Clark
Diabetologia 2007;50:2052-2060
[Full text]
Meta-analysis of the effects of omega-3 polyunsaturated fatty acids on lipoproteins, lipolytic action, oxidation, lipid ratios and other emerging lipid cardiovascular risk markers in type 2 diabetes
J. Hartweg, A. J. Farmer, R. Perera1, R. R. Holman and H. A. W. Neil
Diabetologia 2007;50:1593-1602
[Full text]
Risk Engine
Framingham, SCORE and DECODE do not provide reliable cardiovascular risk estimates in type 2 diabetes
Ruth L. Coleman, Richard J. Stevens, Ravi Retnakaran, and Rury R. Holman
Diabetes Care 2007;30:1292-1293
[Full text]
UKPDS
An Association Analysis of the HLA Gene Region in Latent Autoimmune Diabetes in Adults
M. Desai, E. Zeggini, V. A. Horton, K. R. Owen, A. T. Hattersley, J. C. Levy, M. Walker, K. M. Gillespie, P. J. Bingley, G. A. Hitman, R. R. Holman, M. I. McCarthy and A. Clark
Diabetologia 2007;50:68-73
[Full text] [Abstract]
Meta-analysis of the effects of omega-3 poylunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes
J. Hartweg, A. J. Farmer, R. R. Holman and H. A. W. Neil
Diabetologia 2007;50:250-258
[Full text] [Abstract]
2006Axillary and tympanic membrane temperature measurements are unreliable early after cardiopulmonary bypass
Khan TA, Vohra HA, Paul S, Rosin MD, Patel RL
European Journal of Anaesthesiology 2006;23:551-554
[Full text] [Abstract]
ADOPT
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G for the ADOPT Study Group
N Eng J Med 2006;355:2427-43
[Full text] [Abstract] [Slides]
Erratum in :
N Eng J Med 2007;356:1387-8
ADOPT
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH for the ADOPT Study Group
Diabetic Medicine 2006;23:1289-1294
[Full text] [Abstract]
UKPDS 76
Paraoxonase2 (PON2) Polymorphisms and Development of Renal Dysfunction in Type 2 Diabetes: UKPDS 76
Calle R, McCarthy MI, Banerjee P, Zeggini E, Cull CA, Thorne KI, Wiltshire S, Terra S, Meyer D, Richmond J, Mancuso J, Milos P, Fryburg D, Holman RR
Diabetologia 2006;49:2892-2899
[Full text] [Abstract]
UKPDS Letter
Is there a need for a clinical screening tool for autoimmune diabetes in adults?
Davis TME, Cull CA, Holman RR
Diabetes Care 2006;11:2560
[Full text]
UKPDS 73
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73
Wright AD, Cull CA, Macleod KM, Holman RR for the UKPDS Group
Journal of Diabetes and its Complications 2006;20:402-408
[Full text] [Abstract]
DREAM
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR on behalf of the DREAM trial investigators
Lancet 2006;368:1096-105
Erratum in :
Lancet 2006;368:1770
DREAM
Effect of Ramipril on the Incidence of diabetes
Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR for the DREAM Trial Investigators
N Eng J Med 2006;355:1551-62
UKPDS 75
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study
Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR
Diabetologia 2006;49:1761-1769
[Full text] [Abstract]
UKPDS 74
Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR for the UKPDS study group
Diabetes 2006;55:1832-1839
[Full text] [Abstract]
Outcomes Model Letter
PROactive Study
Holman RR, Retnakaran R, Farmer A, Stevens RJ
Lancet 2006;367:25-26
UKPDS
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective
Holman RR
Metabolism Clinical and Experimental 2006;55 (Suppl 1):S2-S5
[Full text] [Abstract]
UKPDS
The Variable Number of Tandem Repeats Upstream of the Insulin Gene Is a Susceptibility Locus for Latent Autoimmune Diabetes in Adults
Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Hitman GA, Walker M, Holman RR, McCarthy MI, Clark A
Diabetes 2006;55:1890-1894
[Full text] [Abstract]
LDS
Assessing the Impact of Visual Acuity on Quality of Life in Individuals With Type 2 Diabetes Using the Short Form-36
Clarke PM, Simon J, Cull CA, Holman RR
Diabetes Care 2006;29:1506-1511
[Full text] [Abstract]
Algorithm
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B
Diabetes Care 2006;29:1963-1972
Erratum in :
Diabetes Care 2006;49:2816-8
Algorithm
Management of Hyperglycaemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B
Diabetologia 2006;49:1711-1721
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials
Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P
American Heart Journal 2006;152:27-38
[Full text] [Abstract]
ADOPT
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes
Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC and the ADOPT Study Group
Diabetes 2006;55:2357-2364
[Full text] [Abstract]
2005Outcomes Model / UKPDS 72
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR
Diabetologia 2005;48:868-877
[Full text]
UKPDS 71
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes
G. F. Bottazzo, E. Bosi, C. A. Cull, E. Bonifacio, M. Locatelli, P. Zimmet, I. R. Mackay, R. R. Holman
Diabetologia 2005;48:703-708
[Full text]
Erratum in :
Diabetologia 2005;48:1240
UKPDS 70
Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control
T. M. E. Davis, A. D. Wright, Z. M. Mehta, C. A. Cull, I. M. Stratton, G. F. Bottazzo, E. Bosi, I. R. Mackay, R. R. Holman
Diabetologia 2005;48:695-702
[Full text]
Risk Engine Short Report
Framingham risk equations underestimate coronary heart disease risk in diabetes
R. J. Stevens, R. L. Coleman, R. R. Holman
Diabetic Medicine 2005;22:225-228
[Full text]
Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR
Diabetes Care 2005;28:995-1000
[Full text] [Abstract]
Risk Engine Short Report
Non-HDL Cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes
Holman RR, Coleman RL, Shine BS, Stevens RJ
Diabetes Care 2005;28:1796-1797
[Full text]
UKPDS
Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study
Thomason MJ, Biddulph JP, Cull CA, Holman RR
Diabetic Medicine 2005;22:1031-1036
[Full text]
A common mitchondrial DNA variant is associated with thinness in mothers and their 20 year old offspring
Parker E, Phillips DI, Cockington RA, Cull C, Poulton J
American Journal of Physiology, Endocrinology & Metabolism 2005;289:E1110-E1114
[Full text] [Abstract]
2004UKPDS 69
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM for the UK Prospective Diabetes Study Group
Archives of Ophthalmology 2004;122:1631-1640
[Full text]
Outcomes Model / UKPDS 68
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS 68)
P. M. Clarke, A. M. Gray, A. Briggs, A. J. Farmer, P. Fenn, R. J. Stevens, D. R. Matthews, I. M. Stratton, R. R. Holman
Diabetologia 2004;47:1747-1759
[Full text]
UKPDS 67
Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)
Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR
Diabetic Medicine 2004;22:306-311
[Full text] [Abstract]
Risk Engine / UKPDS 66
Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR
Diabetes Care 2004;27:201-207
[Abstract]
Letter
Comparative study of prognostic value for coronary disease risk between the U.K. Prospective diabetes study and framingham models: response to Protopsaltis et al.
Stevens RJ, Holman RR
Diabetes Care 2004;27:1844-1845
Letter
A standardized triglyceride and carbohydrate challenge: response to thanopoulou, karamanos, and roussi
Mohanlal N, Holman RR
Diabetes Care 2004;27:2093
A Standardized Triglyceride and Carbohydrate Challenge
Mohanlal N, Holman RR
Diabetes Care 2004;27:89-94
[Abstract]
UKPDS
Changing aspirin use in patients with Type 2 diabetes in the UKPDS
Cull CA, Neil HAW, Holman RR
Diabetic Medicine 2004;21:1368-1371
[Full text] [Abstract]
DREAM
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial
Gerstein HC, Yusuf S, Holman RR, Bosch J, Pogue J; The DREAM Trial Investigators
Diabetologia 2004;47:1519-1527
[Full text] [Abstract]
Guidelines
Guidelines for computer modeling of diabetes and its complications
Bergemann R, Brown J, Chan W, Clarke P, Eddy D, Herman W, Palmer AJ, Roze S, Stevens R, Zhang P
Diabetes Care 2004;27:2262-2265
2003Outcomes Model / UKPDS 65
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No 65)
Clarke P, Gray A, Legood R, Briggs A, Holman R
Diabetic Medicine 2003;20:442-450
[Full text]
UKPDS 64
Development and Progression of Nephropathy in Type 2 Diabetes: Observation and Modelling from the United Kingdom Prospective Diabetes Study
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR for the UKPDS Group
Kidney International 2003;63:225-232
[Abstract]
UKPDS
Autoantibodies to the islet cell antigen SOX-13 areassociated with duration but not type of diabetes
Davis TM, Mehta Z, Mackay IR, Cull CA, Bruce DG, Fida S, Rowley MJ, Holman RR
Diabetic Medicine 2003;20:198-204
[Abstract]
Diabetes education and knowledge in patients with type 2 diabetes from the community The Fremantle Diabetes Study
Bruce DG, Davis WA, Cull CA, Davis TM
Journal of Diabetes and its Complications 2003;17:82-89
Risk Engine
Evaluation of methods for interval estimation of model outputs, with application to survival models
Stevens RJ
Journal of Applied Statistics 2003;30:967-981
[Full text]
Intensive control policies for blood pressure and blood glucose concentrations in type 2 diabetes are affordable in England
Gray A, Clarke P, Farmer A, Holman RR
Evidence-based Healthcare 2003;7:51-52
[Full text]
UKPDS
Poor pregnancy outcome for women with Type 2 diabetes
Hadden DR, Cull CA, Croft DJ, Holman RR
Diabetic Medicine 2003;20:506-507
2002ISAT
International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling of 2143 patients with ruptured intracranial aneurysms: a randomised trial
Molyneux A, Kerr R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R
J Stroke Cerebrovasc Dis. 2002;11:304-14
UKPDS 63
The economics of translating trial evidence into practice: costs of implementing more intensive glycaemic and blood pressure control in type 2 diabetes in England
Gray A, Clarke P, Farmer A, Holman R for the United Kingdom Prospective Diabetes Study (UKPDS) Group
British Medical Journal 2002;325:1-6
[Full text] [Abstract]
Outcomes Model / UKPDS 62
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
Clarke P, Gray A, Holman R
Medical Decision Making 2002;4:340-349
UKPDS 61
Are Lower Fasting Plasma Glucose Levels at Diagnosis of Type 2 Diabetes Associated with Improved Outcomes?
Colagiuri S, Cull CA, Holman RR
Diabetes Care 2002;25:1410-1417
[Abstract]
Risk Engine / UKPDS 60
Risk of stroke in type 2 diabetes estimated by the UKPDS risk engine
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR
Stroke 2002;33:1776-1781
[Abstract]
UKPDS 59
Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes.
Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR
Diabetes Care 2002;25:894-899
[Abstract]
UKPDS 58
Modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.
Stevens RJ, Stratton IM, Holman RR.
Journal of Diabetes and its Complications 2002;16:371-376
[Abstract]
UKPDS 57
Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study
Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR.
Diabetes Care 2002;25:330-336
[Abstract]
Erratum in :
Diabetes Care 2002;25:1268
Letter
Fire-and-forget in prevention of coronary heart disease.
Karpe F, Holman R.
Lancet 2002;360:1984
UKPDS
Analysis of the United Kingdom Prospective Diabetes Study
Holman RR
Endocrine Practice 2002;8:33-34
[Abstract]
Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes
Gloyn AL, Desai M, Clark A, Levy JC, Holman RR, Frayling TM, Hattersley AT, Ashcroft SJH
Diabetologia 2002;45:58-583
[Abstract]
Prevention Conference VI: Diabetes and Cardiovascular Disease
Grundy SM, Garber A, Goldberg R, Havas S, Holman R, Lamendola C, Howard WJ, Savage P, Sowers J, Vega GL
Circulation 2002;105:e153
A non-invasive frequent home blood glucose monitor.
Lenzen H, Barrow BA, White S, Holman RR.
Practical Diabetes 2002;19:101-103
[Abstract]
ADOPT
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes
Viberti G. Kahn SE. Greene DA. Herman WH. Zinman B. Holman RR. Haffner SM. Levy D. Lachin JM. Berry RA. Heise MA. Jones NP. Freed MI.
Diabetes Care 2002;25:1737-1743
[Full text] [Abstract]
ISAT
International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling of 2143 patients with ruptured intracranial aneurysms: a randomised trial
Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, Holman R; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group
Lancet 2002;360:1267-1274
[Full text] [Abstract]
UKPDS Letter
Calculation of coronary risk in Type 2 diabetes: another cause for concern: authors' reply
Holman RR, Manley SE, Stevens RJ on behalf of the UKPDS Study Group
Clinical Science 2002;103:217-219
UKPDS
Standardization of glycated haemoglobin.
Marshall SM, Home PD, Manley SM, Barth JH, John WG.
Annals of Clinical Biochemistry 2002;39:77-79
Hyperglycaemia siblings of type 2 (non-insulin dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their normoglycaemic sibling
Herlihy OM, Barrow BA, Grant PJ, Levy JC
Diabetologia 2002;45:635-641
[Abstract]
2001Risk Engine / UKPDS 56
The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes
Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group
Clinical Science 2001;101:671-679
[Abstract]
Erratum in :
Clinical Science 2002;102:679
UKPDS 55
Relationship between ethnicity and glycaemic control, lipid profiles and blood pressure during the first nine years of Type 2 diabetes
Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group
Diabetes Care 2001;24:1167-1173
[Abstract]
UKPDS 54
An economic evaluation of atenolol versus captopril in patients with Type 2 diabetes
Gray A, Clarke P, Raikou M, Stevens R, Neil A, Cull C, Stratton I, Holman R
Diabetes Medicine 2001;18:438-444
[Abstract]
UKPDS 53
Association Studies of Variants in Promotor and Coding regions of b-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 Diabetes
Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC.
Diabetic Medicine 2001;18:206-12
[Abstract]
UKPDS 52
Relationship between severity of retinopathy and progression to photocoagulation in type 2 diabetic patients in UKPDS.
Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR.
Diabetic Medicine 2001;18:178-184
[Abstract]
UKPDS 50
Risk factors for incidence and progression of retinopathy in type 2 diabetes over 6 years from diagnosis.
Stratton IM, Kohner EM, Aldington SJ, Turner RC, Manley SE, Matthews DR
Diabetologia 2001;44:1546-163
[Abstract]
UKPDS
Butyrylcholinesterase K variant on chromsome 3q is associated with Type II diabetes in white Caucasian subjects
Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al.
Diabetologia 2001;44:2227-2230
[Abstract]
Erratum in :
Diabetologia 2002;45:459
UKPDS
The UKPDS: implications for the dyslipidaemic patient
Holman R
Acta Diabetologica 2001;38:S9-S14
[Abstract]
UKPDS
Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton IM, Jacques P, Breteler MMB, Holman R
Journal of Cardiovascular Risk 2001;8:363-369
[Abstract]
UKPDS 51
Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes (UKPDS 51).
Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R; UKPDS Group. United Kingdom Prospective Diabetes Study
Diabetologia 2001;44:298-304
[Abstract]
2000UKPDS 35
Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR
British Medical Journal 2000;321:405-412
[Full text] [Abstract] [Slides]
UKPDS
Life-expectancy projection by modelling and computer simulation (UKPDS 46).
Stevens R, Adler A, Gray A, Briggs A, Holman R.
Diabetes Research and Clinical Practice 2000;50:S5-S13
[Abstract]
UKPDS 45
Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins
Manley SM, Stratton IM, Cull CA, Fighi V, Eeley EA, Matthews DR, Holman RR, Turner RC
Diabetic Medicine 2000;17:518-523
[Abstract]
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial
Gray A, Raikou M, McGurire A, Fenn P, Stevens R, Cull C, Stratton IM, Adler AI, Holman RR, Turner RC
British Medical Journal 2000;320:1373-1378
UKPDS 36
Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study
Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR
British Medical Journal 2000;321:412-419
[Full text] [Abstract] [Slides] [Slides #2]
UKPDS Letter
Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed
Holman RR
British Medical Journal 2000;321:1078-1079
[Full text] [Abstract]
Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycaemia
Peacey SR, Robinson R, Bedford C, Harris ND, MacDonald IA, Holman RR, Heller SR
Diabetes Care 2000;23:1022-1023
Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of propectively designed overviews of randomised trials
Blood pressure lowering treatment trialists collaboration
The Lancet 2000;356:1955-1964
[Abstract]
UKPDS 41
Cost-effective analysis of intensive blood glucose control with metformin in overweight patients with type 2 diabetes.
Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R
British Medical Journal 2000;320:1373-1378
[Full text] [Abstract]
Possible prevention of type 2 diabetes with acarbose or metformin
Holman RR, North BV, Tunbridge FK
Diabetes 2000;Suppl 1:1078-1079
1999UKPDS 49
Glycaemic control with diet, sulphonylurea, metformin and insulin therapy in patients with type 2 diabetes: progressive requirement for multiple therapies
Turner RC, Cull CA, Frighi V, Holman RR
JAMA 1999;281:2005-2012
[Abstract]
UKPDS 48
Sequence variants of the sarco(endo)plasmic reticulum Ca2+-transport ATPase 3 gene (SERCA3) are associated with Type 2 diabetes in Caucasians
Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft SJH, Turner RC
Diabetologia 1999;42:1240-1243
[Full text] [Abstract]
UKPDS 47
Hyperglycaemia and hyperinsulinaemia at diagnosis of diabetes and their association to subsequent cardiovascular disease in the UK Prospective Diabetes Study
Adler AI, Neil AW, Manley SE, Holman RR, Turner RC
American Heart Journal 1999;138:S353-S359
[Abstract]
UKPDS 44
Randomised, double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over three years
Holman RR, Cull CA, Turner RC
Diabetes Care 1999;22:960-964
[Abstract]
Erratum in :
Diabetes Care 1999;22:1922
UKPDS 43
Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes
Horton VA, Stratton IM, Bottazzo GF, Shattock M, MacKay I, Zimmett P, Manley SE, Holman RR, Turner RC
Diabetologia 1999;42:608-616
[Abstract]
UKPDS 42
Microaneurysms in the development of diabetic retinopathy
Kohner EM, Stratton IM, Adlington SJ, Turner RC
Diabetologia 1999;42:1107-1112
[Abstract]
UKPDS 37
Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control
UKPDS Group
Diabetes Care 1999;22:1125-1136
[Abstract]
UKPDS 31
Hepatocyte nuclear factor-1a (the MODY3 gene) mutations in late onset Type 2 diabetes in the UK.
Cox RD, Sotham L, Hashim Y, Horton V, Mehta Z, Taghavi J, Lathrop M, Turner RC
Diabetes 1999;42:120-121
UKPDS 29
Risk factors for stroke in non-insulin dependent diabetes mellitus
Davies TME, Millns H, Stratton IM, Holman RR, Turner RC
Archives of Internal Medicine 1999;159:1097-1103
[Abstract]
UKPDS
UKPDS: What was the question? UK Prospective Diabetes Study
Turner R, Holman R, Butterfield J
Lancet 1999;354:600
Metformin and Risk of Cardiovascular Disease
Turner RC, Holman RR
Cardiology 1999;91:203-204
1998UKPDS 40
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes
UKPDS Group
British Medical Journal 1998;317:720-726
[Full text] [Abstract]
UKPDS 39
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes
UKPDS Group
British Medical Journal 1998;317:713-720
[Full text] [Abstract]
UKPDS 38
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
UKPDS Group
British Medical Journal 1998;317:703-713
[Full text] [Abstract]
UKPDS 34
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes
UKPDS Group
Lancet 1998;352:854-865
[Abstract]
Erratum in :
Lancet 1998;352:1558
UKPDS 33
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
UKPDS Group
Lancet 1998;352:837-853
[Abstract]
Erratum in :
Lancet 1999;354:602
UKPDS 32
Ethnicity and cardiovascular disease: the incidence of myocardial infarction in white, south Asian and Afro-Caribbean patients with Type 2 diabetes
UKPDS Group
Diabetes Care 1998;21:1271-1277
[Abstract]
UKPDS 30
Diabetic retinopathy at diagnosis of type 2 diabetes and associated risk factors
UKPDS Group
Archives of Ophthalmology 1998;116:297-303
[Abstract]
UKPDS 28
A randomised trial of efficacy of early addition of metformin in sulphonylurea-treated non-insulin dependent diabetes
UKPDS Group
Diabetes Care 1998;21:87-92
[Abstract]
UKPDS 26
Sulphonylurea failure in non-insulin dependent diabetic patients over 6 years
Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC
Diabetic Medicine 1998;15:297-303
[Abstract]
UKPDS 24
Relative efficacy of sulfonylurea, insulin and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years
UKPDS Group
Annals of internal medicine 1998;128:165-175
[Abstract]
UKPDS 23
Risk factors for coronary artery disease in non-insulin dependent diabetes
UKPDS Group
British Medical Journal 1998 1998;316:823-828
[Abstract]
Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM
Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC
Diabetes Care 1998;21:810-816
[Abstract]
Assessing the potential for alpha-glucosidase inhibitors in prediabetic states
Holman RR
Diabetes Research and Clinical Practice 1998;40:21-S25
[Abstract]
1997UKPDS 27
Plasma lipids and lipoproteins at diagnosis of NIDDM: effects of age and gender
UKPDS Group
Diabetes Care 1997;20:1683-1687
[Abstract]
UKPDS 25
Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
UKPDS Group
Lancet 1997;350:1288-1293
[Abstract]
UKPDS 22
Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM
UKPDS Group
Diabetes Care 1997;20:1435-1441
[Abstract]
UKPDS 21
Low prevalence of the mitochondrial transfer RNA gene (tRNA Leu(UUR)) mutation at position 3243bp in UK Caucasian Type 2 diabetic patients
Saker PJ, Hattersley AT, Barrow B, Hammersley MS, Vorton H, Gillmer MD, Turner RC
Diabetic Medicine 1997;14:42-45
[Abstract]
UKPDS 20
Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects.
UKPDS Group
Journal of Clinical Endocrinology & Metabolism 1997;82:654-657
[Abstract]
FHS 3
Randomised controlled trial of sulphonylurea therapy for subjects with increased fasting glucose levels
FHS group, Karunakaran S, Hammersley MS, Morris RJ, Turner RC, Holman RR
Metabolism 1997;46:56-60
[Full text] [Abstract]
FHS 2
Randomised controlled trial of enforced healthy-living advice in subjects with increased but not diabetic fasting glucose
Fasting hyperglycaemia Study Group, Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC
Metabolism 1997;46:50-55
[Full text] [Abstract]
FHS 1
Subject Identification and Recruitment for a non-insulin-dependent diabetes prevention trial
Fasting Hyperglycaemia Study group, Hammersley MS, Meyer LC, Morris RJ, Manley SE
Metabolism 1997;46:44-49
[Full text] [Abstract]
Approach to maintaining comparability of biochemical data during long-term clinical trials
Cull CA, Manley SE, Stratton IM, Neil HAW, Ross IS, Holman RR, Turner RC, Matthews DR
Clinical Chemistry 1997;43:1913-1918
[Abstract]
UKPDS
Progressive Hyperglycaemia: the UKPDS Experience
Holman RR
Consultant (Supp) 1997;37:530-536
[Abstract]
1996UKPDS 19
Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations
Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, Turner RC
Diabetolgia 1996;39:1505-1511
[Abstract]
UKPDS 18
Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
UKPDS Group
Diabetic Medicine 1996;13:656-662
[Abstract]
UKPDS 17
A nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
UKPDS Group
Annals of Internal Medicine 1996;124:136-145
[Abstract]
HDS 4
Hypertension in Diabetes Study (HDS) IV: Therapeutic requirements to maintain tight blood pressure control
Hypertension in Diabetes Study Group
Diabetologia 1996;39:1554-1561
[Abstract]
Impaired Glucose Tolerance
Holman RR
Diabetic Medicine 1996;13:S5
High prevalence of a missense mutation of the glucokinase gene in gestational diabetic patients due to a founder-effect in a local population
Saker PJ, Hattersley AT, Barrow B, Hammersley MS, McLellan JA, D Lo YM, Olds RJ, Gillmer MD, Holman RR, Turner RC
Diabetologia 1996;39:1325-1328
[Abstract]
UKPDS
The UK Prospective Diabetes Study
Turner RC, Holman RR
Annals of Medicine 1996;28:439-444
[Abstract]
Issues in Management: Diabetes
Holman RR, Neil HAW
Prevention of Cardiovascular Disease. Ed. Lawrence M 1996;OUP:0
Frequency of hypoglycemic episodes during intensive therapy with human insulin
Turner RC, Cull CA, Holman RR
Diabetes Care 1996;19:181-182
Intensive treatment of type 2 diabetes
Turner RC, Rachman J, Holman RR
Home P, Ed. Copenhagen Symposium Diabetes - the Challenge. Copenhage: Medical Forum International 1996;13-16
Randomized controlled pilot trial of a hand-held, patient-oriented, insulin regimen optimizer
Holman RR, Smale AD, Pemberton E, Riefflin A, Nealon JL
Informatics for Health and Social CAre 1996;21:317-326
[Abstract]
UKPDS
U.K. Prospective Diabetes Study
Turner RC, Cull CA, Holman RR
Diabetes Care 1996;19:182-183
1995UKPDS 16
Overview of six years' therapy of type 2 diabetes - a progressive disease
UKPDS Group
Diabetes 1995;44:1249-1258
[Abstract]
UKPDS 15
Relation of renin/angiotensin system gene polymorphisms with microalbuminuria in non-insulin dependent diabetes mellitus
Dudley CRK, Keavney B, Stratton IM, Turner RC
Kidney International 1995;48:1907-1911
[Abstract]
UKPDS 14
Association of ACE insertion/deletion polymorphism with myocardial infarction in non-insulin dependent diabetes (NIDDM)
Keavney BD, Dudley CRK, Stratton IM, Holman RR, Matthews DR, Ratcliffe PJ, Turner RC
Diabetologia 1995;38:948-952
[Abstract]
UKPDS 13
Relative Efficacy of Randomly allocated Diet, Sulphonylurea, Insulin, or Metformin in Patients with newly diagnosed non-insulin dependent diabetes followed for three years
Holman RR, Cull CA, Fox C, Turner RC
British Medical Journal 1995;310:83-88
[Full text] [Abstract]
UKPDS
UK Prospective Diabetes Study: 3-year update
Holman RR for the UKPDS Group
New Horizons in Diabetes Mellitus and Cardiovascular Disease, Current Science Press. Ed Born GVR, Schwartz J. 1995;183-186
UKPDS
Lessons from UK Prospective Diabetes Study
Turner RC, Holman RR
Diabetes Research and Clinical Practice 1995;28:S151-S157
[Abstract]
Insulin therapy in Type II diabetes
Holman RR, Turner RC
Diabetes Research and Clinical Practice 1995;28:S179-S184
[Abstract]
1994UKPDS 12
Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes
Meyer LC, Manley SE, Frighi V, Burden F, Neil HAW, Holman RR, Turner RC
Diabetic Medicine 1994;11:670-677
[Abstract]
UKPDS 11
Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects
Manley SE, Meyer LC, Neil HAW, Ross IS, Turner RC, Holman RR
Diabetic Medicine 1994;11:534-544
[Abstract]
HDS 3
Hypertension in Diabetes Study (HDS) III: Prospective study of therapy in type 2 diabetic patients: efficacy of ACE inhibitor and beta-blocker
Hypertension in Diabetes Study Group
Diabetic Medicine 1994;11:773-782
[Abstract]
Optimised Diabetes Therapy Knowledge-Based Systems: Safety Critical Issues
Nealon JL, Jackson-Smale AD, Holman RR
Proc IEE Colloquium on Knowledge-Based Systems for Safety Critical Applications, London 1994;0
An Advisory Expert System for Diabetes Treatment, Expert Systems 94, Cambridge
Nealon JL, Jackson-Smale AD, Holman RR
Applications and Innovation in Expert Systems II, ed R Milne, SGES Publications 1994;0
1993Intranasal Insulin in Type 1 Diabetes
Holman RR
International Symposium, Hamburg 1993;138-143
UKPDS 9
Relationships of urinary albumin and N-acetylglucosaminidase to glycaemia and hypertension at diagnosis of type 2 (non-insulin-dependent) diabetes mellitus and after 3 months diet therapy
UKPDS Study Group
Diabetologia 1993;36:835-842
[Abstract]
UKPDS 10
Urinary albumin excretion over 3 years in diet-treated Type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia
Cull CA, Manley S, Frighi V, Holman RR, Turner RC
Diabetologia 1993;36:1021-1029
[Abstract]
HDS 2
Hypertension in Diabetes Study (HDS) II: Increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients
Hypertension in Diabetes Study Group
Journal of Hypertension 1993;11:319-325
[Abstract]
HDS 1
Hypertension in Diabetes Study (HDS) I: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complications
(HDS I) Hypertension in Diabetes Study Group
Journal of Hypertension 1993;11:309-317
[Abstract]
UKPDS
L'Etude UKPDS Sur Le Controle De La Glycemie Et De L'Hypertension Arterielle Dans Le Diabete De type 2: Objectifs, Structure Et Resultats Preminiaires
Levy JC, Cull CA, Stratton IM, Holman RR, Turner RC
Journ Annu Diabetol Hotel Dieu 1993;123-37
Availability of Type II Diabetic Families for Detection of Diabetes Susceptibility Genes
Cooke JTE, Page RCL, O'Rahilly S, Levy L, Holman RR, Barrow B, Hattersley AT, Shaw JAG, Wainscoat JS, Turner RC
Diabetes 1993;42:1536-1543
1991UKPDS 8
Study design, progress and performance
Turner RC, Holman RR, Matthews DR, Oakes SF, Bassett PA, Stratton IM, Cull CA, Manley SE, Frighi V
Diabetologia 1991;34:877-890
[Abstract]
Chapter
Oral Agents and Insulin
Holman RR, Turner RC
Textbook of Diabetes . Ed. Pickup J, Williams G 1991;462-476
Autoantibodies to islet amyloid polypeptide in diabetes
Clark A, Yon SM, de Koning EJ, Holman RR
Diabetic Medicine 1991;8:668-673
[Abstract]
Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia
Holman RR, Steemson J, Turner RC
Diabetes Res 1991;18:149-53
[Abstract]
1990UKPDS 7
Response of fasting plasma glucose to diet therapy in newly-presenting Type 2 diabetic patients
UKPDS Study Group
Metabolism 1990;39:905-912
[Abstract]
UKPDS 6
Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors
UKPDS Study Group
Diabetes Research 1990;13:1-11
[Abstract]
Rapid restoration of normoglycaemia using intravenous insulin boluses
Dunnett JM, Steemson J, Sear JW, Turner RC, Holman RR
Diabetes Research 1990;15:151-155
[Abstract]
Insulin use in NIDDM. Rationale based on pathophysiology of disease
Turner RC, Holman RR
Diabetes Care 1990;13:1011-1020
[Abstract]
New Therapeutic Principles in the Treatment of Type II diabtes
Holman RR
Diab Neutr Metab 1990;3:29-33
1988UKPDS 5
Characteristics of newly presenting type 2 diabetic patients: estimated insulin sensitivity and islet beta-cell function
UKPDS Study Group
Diabetic Medicine 1988;5:444-448
[Abstract]
UKPDS 4
Characteristics of newly-presenting type 2 diabetic patients: male preponderance and obesity at different ages
UKPDS Study Group
Diabetic Medicine 1988;5:154-159
[Abstract]
Finger-prick blood samples: full blood counts in general practice
Blasewicz LW, Sichel J, Rees SG, Isaac P, Holman RR
The Practioner 1988;232:988-991
A survey of the perioperative management of the patient with diabetes mellitus
Dunnett JM, Holman RR, Turner RC, Sear JW
Anesthesiae 1988;43:538-542
Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes
Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, Turner RC
Diabetes Research 1988;9:151-160
[Abstract]
Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements
Holman RR, Turner RC
Diabetic Medicine 1988;5:582-588
[Abstract]
Potential benefits of the use of long-acting human insulin in NIDDM
Turner RC, Holman RR
In Proc. 1st International Novo Symposium. Ed R Tattersall 1988;45-49
Insulin for non-insulin dependants?
Holman RR
British Medical Journal 1988;296:1469-1470
[Full text]
Sulphonylurea Failure and Inadequacy
Turner RC, Holman RR, Matthews DR
Excerpta Medica; Satellite Symposium. Ed. D Cameron, S Colagiuri, L Heding, C Kuhl, A Ma, R Mortimer 1988;52-56
Role of basal insulin supplement in therapy of Type 2 diabetes
Holman RR, Turner RC
Satellite Symposium, Australia 1988;November:138-142
[Abstract]
1987Glycosylated Haemoglobin Measurement on Blood Samples taken by patients: An Additional Aid to Assessing Diabetic Control
Holman RR, Jelfs R, Causier PM, Moore JC, Turner RC
Diabetic Medicine 1987;4:71-73
[Abstract]
Type II diabetes of early onset: A distinct clinical and genetic syndrome?
O'Rahilly SP, Spivey RS, Holman RR, Nugent Z, Clark A, Turner RC
British Medical Journal 1987;294:923-928
[Full text] [Abstract]
Quantitative modelling of endocrine diseases as exemplified by diabetes
Turner RC, Rudenski AS, Holman RR, Matthews DR, O'Rahilly SP
Clinical Endocrinology Oxf 1987;Jan 26:107-116
No glycaemic benefit from guar administration in non-insulin-dependent diabetics
Holman RR, Steemson J, Darling P, Turner RC
Diabetes Care 1987;10:68-71
[Abstract]
Pen-sized digital 30-second blood glucose meter.
Matthews DR, Bown E, Watson A, Holman RR, Steemson J, Hughes S, Scott D
Lancet 1987;1:778-779
[Abstract]
Identifying the cause
O'Rahilly SP, Holman RR
Mims Magazine 1987;15 March:23-26
Improvement of beta-cell response by sulphonylurea and its rational use in Type II diabetes
Turner RC, Hosker JP, Holman RR
Medicographia 1987;9:42-45
Sulphonylurea failure in type 2 diabetes: Treatment with a basal insulin supplement
Holman RR, Steemson J, Turner RC
Diabetic Medicine 1987;4:457-462
[Abstract]
Traitement du diabete non insulino-dependant
Turner RC, Holman RR
Journ Annu Diabetol Hotel Dieu 1987;129-301
1986Glycosylated Haemoglobin: comparison of 5 different methods, including measurement on capillary blood samples
Moore JC, Brown EG, Outlaw MC, Jelfs R, Holman RR, Turner RC
Annals Clinical Biochemistry 1986;23:85-91
[Abstract]
Diabetes nomenclature: Classification or grading of severity?
Turner RC, Holman RR, Matthews DR, O'Rahilly SP, Rudenski AS, Braund WJ
Diabetic Medicine 1986;3:216-220
Quantifying diabetic retinopathy - a retinopathy index
Howard-Williams JR, Orde-Peckar C, Holman RR, Turner RC, Bron AJ
Diabetologia 1986;29:761-766
[Abstract]
1985UKPDS 3
Prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes
UKPDS Study Group
Hypertension 1985;7:11-13
[Abstract]
UKPDS 2
Reduction in HbA1c with basal insulin supplement, sulphonylurea, or biguanide therapy in maturity-onset diabetes
UKPDS Study Group
Diabetes 1985;34:793-798
[Abstract]
A practical guide to basal and prandial insulin therapy
Holman RR, Turner RC
Diabetic Medicine 1985;2:45-53
[Abstract]
Patient-orientated metered capillary blood collection
Holman RR, Steemson J, Darling P, Turner RC
Annals Clinical Biochemistry 1985;22:141-143
[Abstract]
The Christmas Feast
Rees SG, Holman RR, Turner RC
British Medical Journal 1985;291:1764-1765
[Full text] [Abstract]
Physiology of insulin secretion: problems of quantity and timing
Matthews DR, Connolly AAP, Holman RR, Turner RC
Netherlands Journal of medicine 1985;28:20-24
[Abstract]
Chapter
Optimizing conventional insulin regimens to improve control
Turner RC, Holman RR
Brittle Diabetes, Ed. John Pickup, Backwell Scientific 1985;200-213
Diabetic coma
Holman RR, Blazewicz LW
Medical Forum 1985;16:4-6
The Oxford experience with Ultratard
Holman RR
Proceedings Third International Hvidore Symposium 1985;0
Continuous infusion of glucose with model assessment measurement of insulin resistance and B-cell function in man
Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Daring P, Brown EG, Turner RC
Diabetologia 1985;28:401-411
Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
Diabetologia 1985;28:412-419
1984Human ultralente insulin
Holman RR, Steemson J, Darling P, Reeves WG, Turner RC
British Medical Journal 1984;288:665-668
[Full text] [Abstract]
Non-uniform distribution of islet amyloid in the pancreas of 'maturity-onset' diabetic patients
Clark A, Holman RR, Matthews DR, Hockaday TDR, Turner RC
Diabetologia 1984;27:527-528
[Abstract]
Insulin treatment of maturity onset diabetes
Turner RC, Holman RR
Minerva Endocrinol 1984;9:233-240
1983UKPDS 1
Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year
UKPDS Study Group
Diabetologia 1983;24:404-411
[Abstract]
Prevention of deterioration of renal and sensory nerve function by more intensive management of insulin-dependent diabetics: a two year randomised prospective study
Holman RR, Dornan TL, Mayon-White V, Howard-Williams J, Orde-Peckar C, Jenkins L, Steemson J, Rolfe R, Smith B, Barbour D, Mcpherson K, Poon PYW, Rizza C, Mann JI, Knight AH, Bron AJ, Turner RC
Lancet 1983;1:204-208
[Abstract]
1982Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes
Turner RC, Matthews DR, Holman RR, Peto J
Lancet 1982;1:596-598
[Abstract]
Induced basal normoglycaemia and altered platelet aggregation in maturity-onset diabetes
Evans RJ, Lane J, Holman RR, Turner RC
Diabetes Care 1982;5:433-437
[Abstract]
A regular meal and insulin infusion regimen: its use in the treatment of acute-onset ketotic diabetes and in stabilisation of poorly-controlled established diabetic subjects.
Davis TME, Holman RR, Eaton PM, Turner RC
Diabetes Care 1982;5:492-496
[Abstract]
Chapter
Ultralente-based insulin regimes in insulin-dependent diabetics
Turner RC, Phillips M, Jones R, Dornan TL, Holman RR
Insulin Update. Skyler JS, Ed. Princeton NJ Excerpta medica 1982;157-174
[Abstract]
Chapter
Treatment of non-insulin dependent diabetes by insulin
Turner RC, Holman RR
Insulin Update. Skyler JS. Ed. Princeton NJ Excerpta Medica 1982;233-246
[Abstract]
Vibration sensory threshold: a guide to the adequacy of dialysis
Read DJ, Feest TG, Holman RR
XIX edition of the proceedings of the EDTA 1982;19:253-7
[Abstract]
1981The basal plasma glucose: A simple relevant index of diabetes
Holman RR, Turner RC
Clinical Endocrinology 1981;14:279-286
[Abstract]
Chapter
Diabetes
Holman RR
Emergency Medicine. Ed Evans RG, Butterworths 1981;29-34
Insulin infusion pump
Holman RR, Turner RC
Lancet 1981;2:41
1980Fasting Blood Glucose Concentrations and treatment of maturity-onset diabetes
Howe-Davies S, Muir A, Holman RR, Turner RC
British Medical Journal 1980;280:1148
[Full text]
Survival in sinoatrial disorder (sick sinus syndrome)
Shaw DB, Holman RR, Gowers JI
British Medical Journal 1980;1:139-141
[Full text] [Abstract]
1979Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes
Holman RR, Turner RC
Diabetes 1979;28:227-230
[Abstract]
HOMA Calculator
Insulin deficiency and insulin resistance interaction in diabetes: Estimation of their relative contributions by feedback analysis from basal plasma insulin and glucose concentrations
Turner RC, Holman RR, Matthews DR, Peto J, Hockaday TDR
Metabolism 1979;28:1086-1096
[Abstract]
A simple and rational twice daily insulin regime. Distinction between basal and meal insulin requirements
Phillips M, Simpson RW, Holman RR, Turner RC
Quarterly Journal of Medicine 1979;191:493-506
[Abstract]
1978Beta cell function during insulin or chlorpropamide treatment in maturity onset diabetes
Turner RC, Holman RR
Diabetes 1978;27:241-246
[Abstract]
Basal normoglycaemia attained with chlorpropamide in mild diabetes
Holman RR, Turner RC
Metabolism 1978;27:539-547
Serum lipids in treated diabetic children and their families
Mann JI, Holman RR, Honour AJ, Hughson WG, Thorogood M, Smith A, Baum JD
Clinical Endocrinology 1978;8:27-33
[Abstract]
Home blood sampling for plasma glucose assay in control of diabetes
Howe-Davies S, Holman RR, Phillips M, Turner RC
British Medical Journal 1978;2:596-598
[Full text] [Abstract]
Automatic lancet for capillary blood sampling
Turner RC, Holman RR
Lancet 1978;2:712
1977Treatment of type IV hypertriglyceridaemia with insulin
Turner, R.C., Holman, R.R., Harding, P.A.
Clinical Science and Molecular Medicine 1977;53:
Comparison of treatment of mild diabetes with a basal insulin supplement or sulphonylurea
Holman, R.R., Harris, E., Harding, P., Turner, R.C.
Clinical Science and Molecular Medicine 1977;52:
Diabetes: The quest for basal normoglycaemia
Holman RR, Turner RC
Lancet 1977;1:469-474
[Abstract]
The fundamental importance of the basal plasma glucose in diabetes
Holman RR, Turner RC
Oxford Medical School Gazette 1977;29:18-23
1976Pathophysiology of diabetes
Turner, R.C., Holman, R.R.
Lancet 1976;2:856
[Full text]
Beta-cell improved by supplementing basal insulin secretion in mild diabetes
Turner RC, McCarthy ST, Holman RR, Harris E
British Medical Journal 1976;1:1252-1254
[Full text] [Abstract]
Insulin rather than glucose homeostasis in the pathophysiology of diabetes
Turner RC, Holman RR
Lancet 1976;1:1272-1274
[Abstract]
HOMA Calculator
Beta cell deficiency in the maturity onset of diabetes
Turner RC, Holman RR
Diabetologia 1976;12:398-399
[Abstract]
A New approach to the Treatment of mild diabetes
Holman RR, Turner RC
Diabetologia 1976;12:398-399
1975Early life of the battered child
Holman RR, Kanwar S
Archives of Disease in childhood 1975;50:78-80
[Abstract]